Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 6/20 | 0.56 |
| ▸ | GRPR | P30550 | 1/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 7/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338573 | 0.97 | GLP1R (0.54) | GLP1RGRPRGCGRNR3C1IL23R | |
| SCHEMBL30208638 | 0.97 | GLP1R (0.57) | GLP1RGCGRIL23R | |
| SCHEMBL29484313 | 0.95 | NPBWR1 (0.55) | GLP1RGRPRGCGRNR3C1IL23R | |
| SCHEMBL29484320 | 0.94 | IL23R (0.53) | GLP1RGRPRGCGRIL23RKEAP1 | |
| SCHEMBL30183034 | 0.94 | GLP1R (0.55) | GLP1RGRPRIL23RCTSLCTSH | |
| SCHEMBL30208639 | 0.94 | GLP1R (0.60) | GLP1RGCGRIL23R | |
| SCHEMBL29670416 | 0.92 | CTSL (0.50) | GLP1RGRPRIL23RCTSLCTSH | |
| SCHEMBL31119241 | 0.92 | IL23R (0.53) | GLP1RGRPRGCGRNR3C1IL23R | |
| SCHEMBL29484310 | 0.91 | CTSL (0.53) | GLP1RGRPRIL23RKEAP1CTSL | |
| SCHEMBL30388309 | 0.91 | IL23R (0.53) | GLP1RGRPRIL23RKEAP1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12290566-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12251395-B2 | RNAS for complement inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2024-04-11 | — | — | US | disclosed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | GLP1R 392/4885GRPR 495/4885GCGR 776/4885 |
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | GLP1R 392/4885GRPR 495/4885GCGR 776/4885 |
| US-12290566-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | GLP1R 392/4885GRPR 495/4885GCGR 776/4885 |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | GLP1R 392/4885GRPR 495/4885GCGR 776/4885 |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | GLP1R 392/4885GRPR 495/4885GCGR 776/4885 |
| US-12251395-B2 | RNAS for complement inhibition | SNRPE, RNASE1, SNRPF | GLP1R 4755/4885GRPR 4563/4885GCGR 4161/4885 |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, ADAM8, MSTN | GLP1R 426/4885GRPR 256/4885GCGR 1593/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | GLP1R 898/4885GRPR 965/4885GCGR 877/4885 |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SNRPE, RNASE1, SNRPF | GLP1R 4755/4885GRPR 4563/4885GCGR 4161/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | GLP1R 1105/4885GRPR 526/4885GCGR 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.